UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 466

Sortiert nach

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Annals of oncology, 2014-11, Vol.25 (11), p.2244-2251

2014

Volltextzugriff (PDF)

Corrections to “Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors”

Annals of oncology, 2015-02, Vol.26 (2), p.445-445

2015

Volltextzugriff (PDF)

597 Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial

European journal of cancer (1990), 2012-11, Vol.48, p.183-183

2012

Volltextzugriff (PDF)

EPH226 Associations between Antimicrobial Susceptibility of Streptococcus Pneumoniae and Disease Severity Outcomes in Older Adults with Invasive Pneumococcal Disease in Sao Paulo, Brazil

Value in health, 2024-06, Vol.27 (6), p.S193-S193

2024

Volltextzugriff (PDF)

Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides

Diagnostic microbiology and infectious disease, 1999-07, Vol.34 (3), p.185-191

1999

Volltextzugriff (PDF)

191 E-3810, an inhibitor of the VEGF and FGF family receptors, inhibits the FGF-dependent growth of tumor cells

European journal of cancer supplements, 2010, Vol.8 (7), p.64-64

2010

Volltextzugriff (PDF)

288 Pharmacokinetics and pharmacodynamics of the novel proteasome inhibitor CEP-18770 during a phase I trial in patients with solid tumor, non-Hodgkin lymphoma or multiple myeloma

European journal of cancer supplements, 2010, Vol.8 (7), p.93-93

2010

Volltextzugriff (PDF)

Prolonged Anti-Tumor Activity of Lucitanib in Advanced Thyroid Cancer

Annals of oncology, 2014-09, Vol.25, p.iv354

2014

Volltextzugriff (PDF)

1032PPROLONGED ANTI-TUMOR ACTIVITY OF LUCITANIB IN ADVANCED THYROID CANCER

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv354-iv354

2014

Volltextzugriff (PDF)

Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer

Annals of oncology, 2012-09, Vol.23, p.ix116-ix117

2012

Volltextzugriff (PDF)

Adaptive Automata in Recommendation Systems

Revista IEEE América Latina, 2011-04, Vol.9 (2), p.152-159

2011

Volltextzugriff (PDF)

Enterococcus faecalis resistant to vancomycin and teicoplanin (VanA phenotype) isolated from a bone marrow transplanted patient in Brazil

The Brazilian journal of infectious diseases, 2001-02, Vol.5 (1), p.40-46

2001

Volltextzugriff (PDF)

First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS149-TPS149

2011

Volltextzugriff (PDF)

Adaptive Data Mining: Preliminary Studies

Revista IEEE América Latina, 2014-10, Vol.12 (7), p.1258-1270

2014

Volltextzugriff (PDF)

Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age

International journal of infectious diseases, 2002-06, Vol.6 (2), p.113-117

2002

Volltextzugriff (PDF)

Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil

Infection control and hospital epidemiology, 2002-01, Vol.23 (1), p.19

2002

Volltextzugriff (PDF)

New Antianginal Nitro Esters with Reduced Hypotensive Activity. Synthesis and Pharmacological Evaluation of 3-[(Nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones

Journal of medicinal chemistry, 1995-01, Vol.38 (1), p.130-136

1995

Volltextzugriff (PDF)

Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice

Peptides (New York, N.Y. : 1980), 1986-11, Vol.7 (6), p.1159-1164

1986

Volltextzugriff (PDF)

A pseudo-outbreak of vancomycin-resistant Enterococcus faecium

Infection control and hospital epidemiology, 2003-06, Vol.24 (6), p.461

2003

Volltextzugriff (PDF)

Antireactive properties of glucosamine sulfate

Arzneimittel-Forschung, 1991-02, Vol.41 (2), p.157

1991

Volltextzugriff (PDF)

Effects of ITF 296 on Epicardial Coronary Artery Diameter During Acute and Long-Term Treatment in the Conscious Dog

Journal of cardiovascular pharmacology, 1995, Vol.26 Suppl 4, p.S26-30

1995

Volltextzugriff (PDF)

Effect of ITF 296 on Total Effective Vascular Compliance in the Anesthetized Dog Under Autonomic Blockade

Journal of cardiovascular pharmacology, 1995, Vol.26 Suppl 4, p.S21-25

1995

Volltextzugriff (PDF)

Anticholecystokinin activities of loxiglumide

Arzneimittel-Forschung, 1987-10, Vol.37 (10), p.1168

1987

Volltextzugriff (PDF)

Protective Effects of ITF 296 in the Isolated Rabbit Heart Subjected to Global Ischemia

Journal of cardiovascular pharmacology, 1995, Vol.26 Suppl 4, p.S44-52

1995

Volltextzugriff (PDF)

Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist

Arzneimittel-Forschung, 1987-06, Vol.37 (6), p.703

1987

Volltextzugriff (PDF)

1 – 25 von 466

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(425)
Mit Volltextzugriff
(397)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Corrections to “Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors”

597 Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial

EPH226 Associations between Antimicrobial Susceptibility of Streptococcus Pneumoniae and Disease Severity Outcomes in Older Adults with Invasive Pneumococcal Disease in Sao Paulo, Brazil

Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides

191 E-3810, an inhibitor of the VEGF and FGF family receptors, inhibits the FGF-dependent growth of tumor cells

288 Pharmacokinetics and pharmacodynamics of the novel proteasome inhibitor CEP-18770 during a phase I trial in patients with solid tumor, non-Hodgkin lymphoma or multiple myeloma

Prolonged Anti-Tumor Activity of Lucitanib in Advanced Thyroid Cancer

1032PPROLONGED ANTI-TUMOR ACTIVITY OF LUCITANIB IN ADVANCED THYROID CANCER

Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer

Adaptive Automata in Recommendation Systems

Enterococcus faecalis resistant to vancomycin and teicoplanin (VanA phenotype) isolated from a bone marrow transplanted patient in Brazil

First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors

Adaptive Data Mining: Preliminary Studies

Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age

Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil

New Antianginal Nitro Esters with Reduced Hypotensive Activity. Synthesis and Pharmacological Evaluation of 3-[(Nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones

Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice

A pseudo-outbreak of vancomycin-resistant Enterococcus faecium

Antireactive properties of glucosamine sulfate

Effects of ITF 296 on Epicardial Coronary Artery Diameter During Acute and Long-Term Treatment in the Conscious Dog

Effect of ITF 296 on Total Effective Vascular Compliance in the Anesthetized Dog Under Autonomic Blockade

Anticholecystokinin activities of loxiglumide

Protective Effects of ITF 296 in the Isolated Rabbit Heart Subjected to Global Ischemia

Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist

Suchergebnisse filtern